Overview
- The Nuclear Regulatory Commission granted a materials license to Oklo’s subsidiary Atomic Alchemy, authorizing receipt, processing, and distribution of isotopes at its Idaho Radiochemistry Laboratory, including limited Ra‑226 with Co‑60 and Am‑241 for calibration.
- Oklo signed an Other Transaction Agreement and secured a Nuclear Safety Design Agreement and preliminary safety design review from the Department of Energy to advance its first Aurora reactor at Idaho National Laboratory, with project timing referenced into 2028.
- The isotope license enables the company’s first potential commercial sales from Idaho, while Oklo’s advanced reactors still require separate NRC approvals before any electricity can be sold.
- Following Q4 and full‑year 2025 results that showed a wider‑than‑expected loss, management outlined higher 2026 capex of roughly $350 million to $450 million and reported substantial liquidity, with cash and securities disclosed around $1.4 billion at year‑end.
- Analysts cut price targets but often kept positive ratings, and filings show insiders sold roughly $170 million of stock in the past 90 days, including March 13 sales by the CEO and CFO at $60 per share.